2. Academic Validation
  3. Pharmacological targeting of the pseudokinase Her3

Pharmacological targeting of the pseudokinase Her3

  • Nat Chem Biol. 2014 Dec;10(12):1006-12. doi: 10.1038/nchembio.1658.
Ting Xie 1,  Sang Min Lim 1,  Kenneth D Westover 2,  Michael E Dodge 3,  Dalia Ercan 3,  Scott B Ficarro 4,  Durga Udayakumar 2,  Deepak Gurbani 2,  Hyun Seop Tae 5,  Steven M Riddle 6,  Taebo Sim 7,  Jarrod A Marto 4,  Pasi A Jänne 3,  Craig M Crews 5,  Nathanael S Gray 8
Affiliations

Affiliations

  • 1 1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Department of Biological Chemistry &Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, USA.
  • 2 Departments of Biochemistry and Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
  • 3 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • 4 1] Department of Biological Chemistry &Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • 5 Department of Molecular, Cellular and Development Biology, Yale University, New Haven, Connecticut, USA.
  • 6 Primary and Stem Cell Systems, Life Technologies Corporation, Madison, Wisconsin, USA.
  • 7 1] Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Korea. [2] KU-KIST Graduate School of Converging Science and Technology, Seoul, Korea.
  • 8 1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Department of Biological Chemistry &Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
PMID: 25326665 DOI: 10.1038/nchembio.1658
Abstract

Her3 (also known as ErbB3) belongs to the epidermal growth factor Receptor Tyrosine Kinases and is well credentialed as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules because it lacks appreciable kinase activity. Here we report what is to our knowledge the first selective Her3 ligand, TX1-85-1, that forms a covalent bond with Cys721 located in the ATP-binding site of Her3. We demonstrate that covalent modification of Her3 inhibits Her3 signaling but not proliferation in some Her3-dependent Cancer cell lines. Subsequent derivatization with a hydrophobic adamantane moiety demonstrates that the resultant bivalent ligand (TX2-121-1) enhances inhibition of Her3-dependent signaling. Treatment of cells with TX2-121-1 results in partial degradation of Her3 and serendipitously interferes with productive heterodimerization between Her3 with either Her2 or c-Met. These results suggest that small molecules will be capable of perturbing the biological function of Her3 and ∼60 Other pseudokinases found in human cells.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100848
    98.04%, Her3/ErbB3 抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z